Tear protein biomarkers of refractive surgery pain

项目摘要 屈光性角膜切削术（PRK）和激光辅助原位角膜磨镶术（LASIK）是 用于矫正屈光不正的外科手术，约有60万例手术 每年在美国举行。一部分（10 - 20%）的个体发展为 屈光手术后的持续性眼痛，这是一个巨大的发病率的来源， 限制工作能力，影响心理健康，并导致严重的自杀意念 例我们假设泪液中的蛋白质调节角膜神经功能， 增加了屈光手术后持续疼痛的风险并导致持续疼痛。所以我们的 研究将使用手术后泪液的蛋白质组学分析来鉴定诊断性生物标志物， 持续性眼部疼痛。我们还将在手术前检查泪液蛋白， 预后生物标志物，预测哪些个体可能在术后发生持续性疼痛。 手术R33阶段研究将使用替代蛋白质组学平台进行分析验证， 以及用于临床验证的额外的新患者群体。这些知识可以导致 更好的预防和治疗算法来对抗这种使人衰弱的状况， 提高生活质量并减少患者痛苦。

PROJECT SUMMARY Photorefractive keratectomy (PRK) and laser-assisted in situ keratomileusis (LASIK) are surgical procedures used to correct refractive errors, with approximately 600,000 surgeries performed in the United States each year. A proportion (10 - 20%) of individuals develop persistent ocular pain after refractive surgery, which is a source of tremendous morbidity, limiting the ability to work, impacting mental health, and leading to suicidal ideation in severe cases. We hypothesize that proteins in the tear fluid modulate corneal nerve function, increasing the risk of and contributing to persistent pain after refractive surgery. As such, our studies will use proteomic analysis of tear fluid after surgery to identify diagnostic biomarkers for persistent ocular pain. We will also examine tear proteins prior to surgery in an effort to identify prognostic biomarkers that predict which individuals are likely to develop persistent pain after surgery. R33 Phase studies will use an alternative proteomics platform for analytical validation, and an additional new patient population for clinical validation. This knowledge can lead to better preventative and therapeutic algorithms to combat this debilitating condition and thus improve quality of life and decrease patient suffering.